Acutus Medical (Acutus Medical) EBIT : $8.23 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Acutus Medical EBIT?

Acutus Medical's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-0.58 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $8.23 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Acutus Medical's annualized ROC % for the quarter that ended in Mar. 2024 was -58.98%. Acutus Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -20.44%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Acutus Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 40.98%.

Acutus Medical EBIT Historical Data

The historical data trend for Acutus Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acutus Medical EBIT Chart

Acutus Medical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-74.77

-96.45

-112.01

34.00

-6.20

Acutus Medical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-2.97	-16.95	-11.75	37.51	-0.58

Competitive Comparison of Acutus Medical's EBIT

For the Medical Devices subindustry, Acutus Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acutus Medical's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Acutus Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Acutus Medical's EV-to-EBIT falls into.

Acutus Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.23 Mil.

Acutus Medical (OTCPK:AFIB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Acutus Medical's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-13.468 * ( 1 - 0% )	/	( (28.144	+	17.522)	/ 2 )
=	-13.468	/	22.833
=	-58.98 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	53.96	-	3.413	-	( 22.403	-	max(0, 18.942	-	46.252	+	22.403	))
=	28.144

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	41.668	-	4.192	-	( 19.954	-	max(0, 9.874	-	34.404	+	19.954	))
=	17.522

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Acutus Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-2.308	/	( ( (4.014 + max(7.489, 0))	+	(3.855 + max(7.23, 0)) )	/	2 )
=	-2.308	/	( ( 11.503	+	11.085 )	/	2 )
=	-2.308	/	11.294
=	-20.44 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(11.353	+	4.278	+	8.218)	-	(3.413	+	0	+	12.947)
=	7.489

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(7.75	+	5.888	+	0.812)	-	(4.192	+	0	+	3.028)
=	7.23

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Acutus Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	8.229	/	20.082
	=	40.98 %

Acutus Medical EBIT Related Terms

Thank you for viewing the detailed overview of Acutus Medical's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Acutus Medical (Acutus Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acutus Medical Inc (OTCPK:AFIB) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

2210 Faraday Avenue, Suite 100, Carlsbad, CA, USA, 92008

Website

https://www.acutusmedical.com

Acutus Medical Inc is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. The company designs, manufactures and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias. Its product portfolio includes Novel access sheaths, Transseptal crossing tools, Diagnostic and mapping catheters, Ablation catheters, Mapping and imaging consoles and accessories, as well as Supporting algorithms and Software programs. It markets and sells its electrophysiology products worldwide to hospitals and electrophysiologists that treat patients with arrhythmias. It has a business presence in the United States and Europe.

Executives

Takeo Mukai	officer: Interim CFO	C/O ACUTUS MEDICAL, INC., 2210 FARADAY AVE., SUITE 100, CARLSBAD CA 92008
Jason K Garland	director	10000 WEHRLE DRIVE, CLARENCE NY 14031
Kevin Mathews	officer: SVP, Global Sales	C/O ACUTUS MEDICAL, INC., 2210 FARADAY AVE., SUITE 100, CARLSBAD CA 92008
Charlie Piscitello	officer: Chief People Officer	2210 FARADAY AVE #100, CARLSBAD CA 92008
Tom Sohn	officer: SVP, Gen. Counsel & Secretary	2210 FARADAY AVE #100, CARLSBAD CA 92008
R Scott Huennekens	director	C/O VOLCANO CORPORATION, 11455 EL CAMINO REAL, SUITE 460, SAN DIEGO CA 92130
James F. Hinrichs	director	3750 TORREY VIEW COURT, SAN DIEGO CA 92130
Niamh Louise Pellegrini	director	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Orbimed Rof Ii Llc	director, 10 percent owner	601 LEXINGTON AVE., 54TH FLOOR, NEW YORK NY 10022
David P Bonita	director, 10 percent owner	C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
James E Flynn	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Orbimed Capital Gp Iv Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
John F Sheridan	director	C/O TANDEM DIABETES CARE, INC., 11045 ROSELLE STREET, SAN DIEGO CA 92121
David Roman	officer: SVP & Chief Financial Officer	ACUTUS MEDICAL, INC., 2210 FARADAY AVE, SUITE 100, CARLSBAD CA 92008